Lake Country Advisors

AUGUST 8, 2024

Accurate and appropriate valuation is one of the pillars of maximizing the profits from a business sale. However, company valuation isn’t as simple as slapping a price on your business. It’s a delicate balancing act, as inaccurate valuations have polarizing consequences.

Valuation 97

Valuation Discounted Cash Flow S&P DCF Analysis 97

Cooley M&A

JANUARY 19, 2023

The Inflation Reduction Act imposes a 1% excise tax on certain repurchases of stock of publicly traded US corporations (“Covered Corporations”) effected after December 31, 2022 (the “Excise Tax”). [1] This post highlights key guidance from the Notice as it relates to common M&A and capital market transactions.

M&A 52

M&A Capital Market Stock Mergers and Acquisitions 52

Focus Investment Banking

AUGUST 6, 2023

ESG isn’t just a matter for large, publicly traded companies. This is particularly true if your partners are publicly traded or foreign-owned. Companies that can demonstrate strong ESG programs are more likely to command greater valuations when it comes to a sale.

Middle Market 52

Middle Market Business Government Profitability 52

Cooley M&A

JANUARY 25, 2023

Amid depressed valuations, biotechnology companies also saw an increasing number of demands from activist investors that in certain cases led to more deal activity. It’s a more challenging market environment right now than we’ve seen in many years,” said Charlie Kim , who co-chairs Cooley’s capital markets practice.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

OCTOBER 29, 2020

On September 24, Cooley M&A partner, Garth Osterman, moderated a webinar on the current trend in going public: SPACs! Given that a SPAC is an alternative means to going public, a significant portion of the webinar was dedicated to discussing some of the key differences—and similarities—between a SPAC and a traditional IPO.

M&A 52

M&A IPO Valuation Mergers and Acquisitions 52

Cooley M&A

JANUARY 22, 2020

If, however, capital markets and the economy weaken in 2020, M&A transactions may be the only viable option for life sciences companies to access capital, in which case we would expect to see more M&A transactions by number, but they would likely be paired with lower purchase prices and/or more highly structured.

M&A 40

M&A Pharmaceutical Acquisitions Capital 40

Cooley M&A

JANUARY 22, 2021

Despite dealmaking anxieties in the first half of the year, valuations remained strong, and discount opportunities were few and far between. But given the number of SPACs that went public in 2020 and have yet to announce a business combination (204 of 247), expect to see many more SPAC business combinations in 2021.

M&A 40

M&A IPO Mergers and Acquisitions Business 40